Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-IIAndreas Dietz, Ulrich Keilholz, Gunnar Wichmann et al.|Annals of Oncology|2018Cited by 83
RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trialDaniel Martin, Emmanouil Fokas, Panagiotis Balermpas et al.|Clinical and Translational Radiation Oncology|2020Cited by 33
Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neckThomas Kuhnt, Jürgen Dunst, Andreas Schreiber et al.|Strahlentherapie und Onkologie|2017Cited by 8
Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trialSusanne Wiegand, Andreas Dietz, Gunnar Wichmann et al.|Frontiers in Oncology|2023Cited by 5
Phase II trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell carcinoma of the head and neck (LA SCCHN): Feasibility and 2-year OS.Thomas Kuhnt, Juergen Dunst, Andreas Schreiber et al.|Journal of Clinical Oncology|2013Cited by 3